To date, two forms of microsatellite instability (MSI) have been described in human cancer. MSI typical of hereditary nonpolyposis colon cancer (HNPCC), is due to deficient DNA mismatch repair (MMR) and is defined with mono-and dinucleotide repeat microsatellites. A second variety of instability is best seen at selective tetranucleotide repeats (EMAST; elevated microsatellite alterations at select tetranucleotides). While MSI occurs infrequently in bladder cancers, EMAST is common. Sporadic tumours with the largest proportion showing MSI are those found most frequently in HNPCC kindreds. While bladder cancer is not frequently seen in HNPCC, upper urinary tract tumours (UTTs) are. Having previously found a low frequency of MSI in bladder cancer, we sought to determine the relative levels of MSI and EMAST in transitional cell carcinoma (TCC) of the upper and lower urinary tracts. Microsatellite analysis was performed at 10 mono-and dinucleotide and eight tetranucleotide loci, in 89 bladder and 71 UTT TCC. Contrasting patterns of instability were seen in urinary tumours. In bladder cancer, MSI was rare and EMAST was common. The presence of EMAST was not related to tumour grade, stage, subsequent outcome or immunohistochemical expression of the MMR proteins. In UTT, while MSI occurred frequently, EMAST was seen less frequently than in bladder cancer. When TCC of the upper and lower urinary tracts are compared, MSI-H is more frequent in UTT and EMAST more frequent in bladder cancer. Our findings show that, as for colorectal cancer, the pattern of MSI varies with location in the urinary tract. In addition, we have confirmed that MSI and EMAST are discrete forms of MSI, and that the presence of EMAST does not affect tumour phenotype.
To date, two forms of microsatellite instability (MSI) have been described in human cancer. MSI typical of hereditary nonpolyposis colon cancer (HNPCC), is due to deficient DNA mismatch repair (MMR) and is defined with mono-and dinucleotide repeat microsatellites. A second variety of instability is best seen at selective tetranucleotide repeats (EMAST; elevated microsatellite alterations at select tetranucleotides). While MSI occurs infrequently in bladder cancers, EMAST is common. Sporadic tumours with the largest proportion showing MSI are those found most frequently in HNPCC kindreds. While bladder cancer is not frequently seen in HNPCC, upper urinary tract tumours (UTTs) are. Having previously found a low frequency of MSI in bladder cancer, we sought to determine the relative levels of MSI and EMAST in transitional cell carcinoma (TCC) of the upper and lower urinary tracts. Microsatellite analysis was performed at 10 mono-and dinucleotide and eight tetranucleotide loci, in 89 bladder and 71 UTT TCC. Contrasting patterns of instability were seen in urinary tumours. In bladder cancer, MSI was rare and EMAST was common. The presence of EMAST was not related to tumour grade, stage, subsequent outcome or immunohistochemical expression of the MMR proteins. In UTT, while MSI occurred frequently, EMAST was seen less frequently than in bladder cancer. When TCC of the upper and lower urinary tracts are compared, MSI-H is more
Introduction
Inherited defects in DNA mismatch repair (MMR) genes, usually hMLH1 or hMSH2, lead to microsatellite instability (MSI) and subsequent malignancy in hereditary nonpolyposis colon cancer (HNPCC) (Aaltonen et al., 1993) . While typical of HNPCC cancers, MSI also occurs in a minority of sporadic human cancers (Arzimanoglou et al., 1998) . When present, MSI occurs at a high frequency throughout the genome, causing frameshift mutations within genes containing simple sequence repeats. Thus, MSI-H tumours have a distinctive genotype and subsequent phenotype (Gryfe et al., 2000) . To standardize the investigation of MSI, the Bethesda consensus panel of mono-and dinucleotide repeat loci was established (Boland et al., 1998) . Using an initial five loci (and an additional five in equivocal cases), this panel separates those tumours with high levels of MSI (MSI-H, typical of HNPCC) from those with low levels of MSI (MSI-L) and MSS, both not related to MMR deficiency. While MSI is not solely a phenomenon of repetitive mono-and dinucleotides, this panel was found to be reproducible and representative of tumours with MMR deficiency (Dietmaier et al., 1997) .
Conflicting reports of the frequency of MSI in many tumours have been published, for example, 0-100% in transitional cell carcinoma (TCC) of the bladder (Christensen et al., 1998; Bonnal et al., 2000) . This variation may, in part, be due to differences in the microsatellites studied. Mao et al. (1994) and Gleeson et al. (1996) reported that higher frequencies of instability are seen at tetranucleotide than mono-and dinucleotide repeats in lung, head and neck and bladder, and oesophageal tumours, respectively, and when MSI-H tumours are excluded a subset of tumours with instability at selected tetranucleotides remains. This form of instability appears unrelated to the MSI typical of HNPCC and has been termed EMAST (elevated microsatellite alterations at select tetranucleotides) (Boland et al., 1998) . The high frequency of EMAST, approximately 40% in bladder TCC (BC) (Mao et al., 1994; Danaee et al., 2002) , coupled with its use in LOH detection, has led to the successful use of urinary microsatellite analysis in tumour diagnosis (Steiner et al., 1997) . It is unclear if EMAST tumours, as for MSI-H, have a distinctive genotype and phenotype, although associations with mutant p53 have been described (Ahrendt et al., 2000; Danaee et al., 2002) .
We have recently defined that MSI-H, according to the Bethesda panel is rare (1%) in sporadic BC (Catto et al., 2003) . This low frequency is similar to previous reports (Gonzalez-Zulueta et al., 1993; Linnenbach et al., 1994; Li et al., 1996; Bonnal et al., 2000) , and is not surprising since an increased incidence of BC is not seen in HNPCC (Watson and Lynch, 1993) . Sporadic tumours with the highest proportion showing MSI-H are those found commonly in the HNPCC spectrum, for example, colon (12%), stomach (14%) and endometrial (11%) (Arzimanoglou et al., 1998) . It is of interest that upper urinary tract tumours (UTTs) are found at an increased incidence in HNPCC kindred's (relative risk ¼ 22, Po0.001 (Watson and Lynch, 1993) ). Hartmann et al. (2002) have recently reported that an increased frequency of MSI-H is present in UTT (21%), using the Bethesda microsatellite panel. We sought to define the relationship of the two forms of MSI in urinary cancers, by investigating the frequency of MSI and EMAST in both UTT and BC.
Results

MSI at mono-and dinucleotide repeats in upper urinary tract TCC
We initially investigated the frequency of MSI, according to the full Bethesda panel (five initial and five additional loci) in UTT (Figure 1 ). Of the 71 UTT studied, nine (13%) were MSI-H and 10 (14%) were MSI-L (Table 1 ). As seen in Table 2 , instability was present in approximately 6-13% of tumours at each locus of the Bethesda panel. In 12/19 UTT, the initial five Bethesda loci (BAT25, BAT26, APC, MFD15 and D2S123) correctly defined the MSI status of the tumour. Using the additional five Bethesda microsatellite loci, six new MSI-L UTT were detected and one UTT was converted to MSI-H from MSI-L (Patient H6). Instability was equal at mono-and dinucleotide loci, in contrast to other reports (Hartmann et al., 2002) . When compared with our previously published results showing 1% (1/89) MSI-H and 7% (6/89) MSI-L in bladder cancer, MSI-H is significantly more frequent in UTT than bladder cancer (P ¼ 0.003). However, no significant difference in the incidence of MSI-L, 14% for UTT and 7% for bladder (P ¼ 0.2), was present. Those UTT with MSI-H were more likely to occur in the ureter (7/9, P ¼ 0.019), not be muscle invasive (8/9, P ¼ 0.013) and have an inverted growth pattern (8/9, P ¼ 0.02) when compared with MSI-L and MSS tumours, in agreement with observations by Hartmann et al. (2002) . In contrast, there was little difference for both the patient's average age (67 years old (MSI-H) versus 68 years old) and the grade of tumour differentiation (P ¼ 0.2), between those tumours with MSI-H and other UTT. There was a trend towards an increased incidence of MSI-H UTT in women (5/9), although this failed to reach significance (P ¼ 0.27).
Frequency of EMAST in bladder TCC
Next, we investigated the frequency of EMAST in BC. Using 89 BC, we performed analysis for eight tetranucleotide loci, which have been previously shown to detect the presence of EMAST (Xu et al., 2001) . In total, 40 (45%) bladder tumours had EMAST instability, of which 13 (15%) showed alterations at multiple loci (Table 3 ). All loci showed instability in at least one tumour, with three loci (D20S82, ACTBP2 and UT5320) having more than 10% instability ( Table 2 ). The loci with least alterations, LI7868 (4.1%) and UT5037 (3.9%), contributed to the detection of only five tumours, each with instability at one locus. Thus, the most informative six loci, detected 35/40 TCC with EMAST, including 12/13 TCC with EMAST at multiple loci. When tumours with EMAST are compared with those with MSI, the one MSI-H bladder cancer case had instability at only one EMAST locus (UT5320) and 50% (3/6) of the MSI-L tumours had no instability at EMAST loci. When compared with MSI-H in bladder cancers, the incidence of EMAST in bladder cancer was significantly higher (EMAST at any locus, Po0.00001; EMAST at multiple loci, Po0.00001). The presence of EMAST was seen equally across all pathological stages and grades of BC (Table 3) . When compared with non-EMAST tumours, neither EMAST at multiple nor single loci was associated with a particular tumour stage and grade, or subsequent tumour relapse rates (log rank, P ¼ 0.7). Importantly, the presence of EMAST was not related to the immunohistochemical expression of either of the MMR proteins, hMLH1 and hMSH2. While EMAST was not associated with the patient's age, sex or current status of cigarette smoking, a trend towards increased levels of EMAST instability with increased cigarette exposure was seen. This was true for both the total number of years smoked (average 55 years for EMAST 41 loci versus 34.5 years for EMAST o1) and number of pack years (48 pack years for EMAST 41 loci versus 34 pack years for EMAST o1). 
Frequency of EMAST in upper urinary TCC
Having identified the most informative loci, we then performed EMAST analysis on the 71 UTT. Six loci were studied (Table 2) . EMAST was present in 16(23%) UTT, of which six (9%) had EMAST at multiple loci. Thus, the frequency of EMAST is significantly lower in UTT than bladder cancer (P ¼ 0.009). It is known that MMR-deficient tumours and cells have instability at tetranucleotide in addition to mono-and di-nucleotide repeats (Bhattacharyya et al., 1994; Samowitz et al., 2001) . To define the frequency of those UTT and BC with instability only at the EMAST loci, those tumours that had both EMAST instability and MSI-H were removed from the total number of EMAST tumours. As a result, there were 39 EMAST-only BCs and 10 EMAST-only UTTs, P ¼ 0.0004. It is interesting to note that 5/6 UTT with EMAST at multiple loci were also MSI-H. Thus, instability solely at select tetranucleotides occurs infrequently in UTT.
Immunohistochemical expression of hMLH1 and hMSH2 in upper urinary TCC To investigate the relationship of MSI-H and EMAST in UTT with the expression of the MMR proteins, we performed immunohistochemistry for hMLH1 and hMSH2 (Figure 2 ). In total, 69 out of 71 UTT were successfully immunostained. Absent expression of hMSH2 was seen in 20 (29%) tumours, of which the majority were of low stage (10 pTa and seven pT1) and low grade (four grade 1 and 13 grade 2). The hMLH1 expression was absent in 27 (39%) UTT, and was also seen more frequently in tumours of a low stage (13 pTa and seven pT1) and low grade (two grade 1 and 15 grade 2). When compared with tumours with normal MMR expression, there was a significant association between tumours with reduced MMR expression and low pathological stage (hMSH2 P ¼ 0.02, hMLH1 P ¼ 0.02 and both MMR proteins absent P ¼ 0.02) and low grade (hMSH2 P ¼ 0.003 and both P ¼ 0.04). Seven of the nine MSI-H UTT had absent expression of either protein (two absent hMSH2, two hMLH1 and three both). When compared with MSI-L and MSS UTT, tumours with MSI-H were significantly associated with absent expression of either MMR protein (P ¼ 0.035). In contrast, no association was present between tumours with or without instability at EMAST loci and MMR expression (EMAST-H P ¼ 0.2 and any EMAST P ¼ 0.96).
Discussion
Our results, when taken together, provide evidence that the two forms of MSI occur at different frequencies in the urinary tract. While EMAST is present throughout the urinary tract, MSI-H usually occurs discretely in the upper tracts. We suggest that this pattern is likely to reflect different exposure levels of the regions of the urinary tract to the aetiological agents.
That MSI-H is rare in bladder cancer and common in upper tract tumours, especially the ureter, is a further example of the anatomical specificity of MSI-H tumours. The first reports of this specificity emerged for colon cancer (Thibodeau et al., 1993) , with significantly more MSI-H tumours in the proximal than distal colon, and followed in gastric cancer, with a high frequency of MSI-H tumours in the antrum (Ottini et al., 1997) . While the majority of MSI-H sporadic colorectal cancers show reduced immunohistochemical expression of hMLH1 (Thibodeau et al., 1993) , hMLH1 mutations are infrequent in these tumours. Subsequent work (Herman et al., 1998) has shown that, in contrast to HNPCC tumours in which gene mutation is responsible for MMR loss, in MSI-H sporadic cancers promoter hypermethylation is responsible for reduced expression of hMLH1. Additional studies have shown that MSI-H sporadic tumours are characterized by aberrant hypermethylation in many genes, when compared with MSS tumours (Kuismanen et al., 1999) . In contrast, the mechanism of reduced hMSH2 expression (when present in MSI-H sporadic colorectal cancers) does not appear to be from promoter hypermethylation, but rather by sporadic gene mutation or unrecognized cases of HNPCC families.
In our series, most MSI-H tumours had absent expression of one or both MMR proteins. While the mechanism for the high frequency of MSI-H in UTT remains to be investigated, studies of mixed To date, those tumours showing the highest levels of EMAST are associated with known environmental carcinogens, for example, cigarette smoking or sunlight exposure, suggesting a causal relationship. For example, EMAST is common in head and neck (56%), lung (51%) and bladder cancer (21-40%), but infrequent in renal (12%) and prostate cancer (6%) (AR Azzouzi, data not shown) (Xu et al., 2001; Danaee et al., 2002) . While, to the best of our knowledge, the EMAST markers have not been studied in colorectal cancers, Samowitz et al. (2001) found that tetranucleotide instability was present usually in those colorectal cancers with MSI-H, with only 1.3% of cases being MSS with tetranucleotide instability. Slebos et al. (2002) have recently produced evidence to support the association of EMAST with environmental carcinogens. Using a modified colorectal cancer cell line (RKO, defective in hMLH1 to allow the persistence of any nucleotide changes), the authors used environmental carcinogens, for example g and UV irradiation, benzo(a)pyrene diol epoxide, N-methyl-N-nitro-N-nitrosoguanidine (MNNG), to induce tetranucleotide instability. Considering that the bladder stores urine, its urothelium is exposed for longer to mutagens potentially inducing EMAST than the upper tract, which receives transient urine exposure. While the lack of significant correlation between a smoking history and EMAST in our study may argue against this, it was notable that tumours with EMAST at multiple loci were found in patients with the longest and highest levels of smoking. Thus, it is possible that as either smoking or environmental agents cause most TCC, the contribution of smoking over that from the exposure to environmental agents is not sufficient to be seen in our small series.
To conclude, we have shown that the urinary tract, as for the colon and stomach, shows an anatomical variation in the frequency of MSI-H tumours. Tumours of the upper urinary tract, in particular the ureter, have a high frequency of MSI-H (associated with reduced MMR expression) in keeping with their increased incidence in HNPCC. Instability at select tetranucleotides (EMAST) is not associated with reduced MMR expression and is seen more frequently in bladder cancers. This may reflect an increased and prolonged exposure to environmental carcinogens. Both forms of MSI appear unrelated and often occur discretely, depending upon location. 
Materials and methods
Patients
In all, 160 patients with primary TCC were studied, of which 89 were bladder tumours and 71 upper UTTs. The specimens were collected from the Royal Hallamshire Hospital, Sheffield, UK (all bladder tumours and 27 UTT) and the Hoˆpital Tenon (21 UTT) and Institut Mutualiste de Montsouris (23 UTT), both in Paris, France. The tumours were graded using the WHO classification and staged according to the 1997 TNM classification. The BCs were composed of 60 superficial tumours (37 well or moderately differentiated and noninvasive (G2-3 pTa) and 23 poorly differentiated tumours invading the lamina propria (G3 pT1)) and 29 muscle invasive TCCs (pT2-4), of which 27 were poorly differentiated. The UUTs were composed of 44 tumours arising in the renal pelvis, 25 in the ureter and two in both. There were 29 noninvasive (pTa), 15 superficially invasive (pT1) and 27 muscle invasive (pT2-3) UTT. The BC and UTT populations had similar median ages, 67 and 68 years, respectively, and proportion of females (33%). One UTT patient (Patient 123) had a family history suggestive of HNPCC. All BC patients had clinical follow-up of at least 5 years (median 5, range 5-16 years) or until death, following the first resection of their tumour. Comprehensive smoking data, including daily consumption, years smoked and total exposure, was present for 87 BC patients. For analysis, 'relapse' was defined as the presence of a further TCC, regardless of histological stage and grade, following the removal of the original tumour. Local ethics committee approval was granted, and informed consent was obtained from all patients prior to the commencement of the study.
Microdissection and DNA extraction
DNA was extracted from 6 Â 10 mm thick formalin-fixed, paraffin-embedded tissue sections. After marking by a pathologist, each section was microdissected to give enriched (480%) tumour tissue and normal (bladder muscle or kidney) tissue. DNA was extracted from the microdissected tissue using the QIAamp s (QIAGEN, UK) kit, following the manufacturer's recommended protocol.
Microsatellite analysis
Microsatellite analysis was performed for each TCC using paired normal and tumour DNA. The microsatellites studied were composed of the Bethesda consensus panel (BAT25, BAT26, MFD15 (D17S250), D2S123, APC (D5S346), BAT40, D10S197, MYC1L, D18S58, D18S69) (Boland et al., 1998) and eight tetranucleotide loci shown to detect the presence of EMAST (UT5320, ACTBP2, CSF1R, D20S82, D11S488, D9S242, LI7686, UT5037) (Xu et al., 2001) . LI7686 and UT5037 were found to detect infrequently EMAST in BC, and therefore were not studied in the UTT. PCR using fluorescence-labelled primers (MWG Biotech, UK) was performed for each sample at each locus. The primer sequences have been published previously (Dietmaier et al., 1997; Xu et al., 2001) . PCR was performed in a 12 ml volume reaction, composed of 1 pmol fluorescence labelled forward and unlabelled reverse primers, 50 ng of DNA template and a premade PCR mastermix solution of Taq DNA polymerase, dNTPs, 1.5 mm MgCl 2 and buffers (Abgene, Surrey, UK). For each microsatellite locus a standard reaction was performed with 35 cycles of amplification using a 'Priamus 96' thermal cycler (MWG Biotech, UK). Each cycle consisted of denaturation (951C for 30 s), annealing and extension (721C for 30 s). Annealing temperatures varied for each microsatellite locus and are listed elsewhere (Catto et al., 2003) . Analysis of the PCR products was performed on an automated LICOR sequencer (MWG Biotech, UK). The presence of extra or shifted bands was classified as MSI. For each case of MSI, the PCR reaction was independently repeated to confirm the result. All loci were studied in each tumour. When no product was detected after PCR, the reaction was repeated twice to confirm that no amplification was possible. While the presence 
Immunohistochemical detection of hMLH1 and hMSH2 protein expression
Immunohistochemistry was used to demonstrate hMLH1 and hMSH2 protein expression in the UTT. The immunohistochemical expression of hMLH1 and hMSH2 in these BC has been previously reported (Catto et al., 2003) . Briefly, 5 mm thick sections from a tissue microarray (TMA) containing formalin-fixed, paraffin-embedded UTT were mounted on APES-coated slides and dried, before deparaffination in xylene and rehydration in decreasing concentrations of alcohol. Endogenous peroxidase activity was blocked, before antigen retrieval (microwave for 10 min) in 10 mm trisodium citrate solution (pH 6.0). The sections were then rinsed in PBS before being incubated in the primary antibody buffer (horse serum) for 30 min. After rinsing, the sections were incubated with the primary monoclonal antibody. The monoclonal antibodies were: anti-hMLH1 (13291A, Clone G168-728, Pharmingen, San Diego, CA, USA) used at a dilution of 1 : 1000 and incubated for 1 h at room temperature; and Ab-1 anti-hMSH2 (Clone GB12, Oncogene, Cambridge, MA, USA) at a dilution of 3 : 100 and incubated overnight at 41C. The primary antibodies were visualized with the Vectastain Elite ABC kit (Vector Laboratories, CA, USA). The secondary and tertiary antibodies were incubated for 30 min each. Diaminobenzidine (Vector Laboratories, CA, USA) and peroxide were used to develop the primary antibody before counterstaining with Gill's haematoxylin. Both positive (normal colonic mucosa) and negative (specimens incubated with no primary antibody) controls were used at all stages.
Immunohistochemical scoring
The sections were scored according to previously validated criteria (Catto et al., 2003) , by two investigators (JWFC and KFM). Briefly, those sections with 0-20% of positively stained nuclei, indicating a lack of the appropriate repair protein, were scored as abnormal ('absent'). Those sections with 420% of stained nuclei were scored as normal ('present').
Statistical analyses
The relationships between MSI, EMAST and the various clinicopathological data were calculated using w 2 and Fisher's exact tests. For continuous variables, such as patient's age and smoking exposure (total years, and pack years), a Student's t-test was used. The relapse probability, as a function of time, was plotted using the Kaplan-Meier method and compared using log-rank analysis. Patients who died from non-TCC causes were considered censored data from the time of death. A P-value of o0.05 was interpreted as statistically significant.
